UPDATE: Goldman Sachs Starts Editas Medicine (EDIT) at Sell, Cautious on Lead Drugs

April 16, 2021 3:08 AM EDT
Get Alerts EDIT Hot Sheet
Price: $31.40 -1.01%

Rating Summary:
    9 Buy, 6 Hold, 5 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 9 | New: 37
Trade Now! 
Join SI Premium – FREE
(Updated - April 16, 2021 4:14 AM EDT)

Goldman Sachs analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Sell rating and a price target of $20.00.

The analyst comments "Our 12-month price target of $20 implies 52% downside potential. We remain cautious on the CRISPR gene editing (GE) firm’s lead drugs, EDIT-101 for IVS26 Leber’s congenital amaurosis type 10 (LCA10) and EDIT-301 for sickle cell disease (SCD) and β-thalassemia (β-Thal). We think the risk-reward dynamic is skewed negatively into 2021 EDIT-101 data and YE21 EDIT-301 dosing commencement."

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $40.98 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Goldman Sachs